World Allergy Organization Journal最新文献

{"title":"Exploring trends and predictors of long-term asthma remission","authors":"Vera Veith PhD ,&nbsp;Frauke Pedersen PhD ,&nbsp;Henrik Watz MD PhD ,&nbsp;Anne-Marie Kirsten MD ,&nbsp;Folke Brinkmann MD (Prof) ,&nbsp;Matthias V. Kopp MD (Prof) ,&nbsp;Anna-Maria Dittrich MD (Prof) ,&nbsp;Gesine Hansen MD (Prof) ,&nbsp;Nicole Maison MD ,&nbsp;Bianca Schaub MD (Prof) ,&nbsp;Erika von Mutius MD (Prof) ,&nbsp;Klaus F. Rabe MD (Prof) ,&nbsp;Thomas Bahmer MD (Prof) ,&nbsp;Mustafa Abdo MD PhD ,&nbsp;the ALLIANCE Study Group","doi":"10.1016/j.waojou.2025.101127","DOIUrl":"10.1016/j.waojou.2025.101127","url":null,"abstract":"<div><h3>Rationale</h3><div>Asthma remission is a state of low to no disease activity. To date, little is known about predictors and the achievability of long-term asthma remission.</div></div><div><h3>Objective</h3><div>To identify clinical predictors and trends of long-term remission in a cohort of adults with mild to severe asthma.</div></div><div><h3>Methods</h3><div>This study included 203 adults with mild to severe asthma from the All Age Asthma Cohort, followed over 6 years. Participants attended 5 visits, during which type 2 inflammation markers (blood and sputum eosinophils, fractional exhaled nitric oxide), lung function measurements (oscillometry, spirometry), atopy and systemic comorbidities were assessed. Clinical remission was defined by an Asthma Control Test score of ≥20 plus the absence of both severe exacerbations and systemic corticosteroid use in the past 12 months, and normal or stable lung function. Long-term remission was defined as remission lasting at least 3 consecutive years, while short-term remission lasted 1 or 2 consecutive years.</div></div><div><h3>Results</h3><div>The frequencies of long-term, short-term, and no remission were 27%, 34%, and 39%, respectively. 16% of all patients with severe asthma achieved long-term remission, compared to 65% of those with mild-to-moderate disease. Over one-third of all patients never achieved remission and had persistent T2 markers despite high-dose ICS. Predictors of no asthma remission included number of persistent T2-markers (OR:0.26, CI: 0.11, 0.61), frequency dependence of resistance (FDR, R5-R20Hz; OR:0.36, CI: 0.15, 0.82), FEV1/FVC (OR:0.16, CI: 0.06, 0.37), GERD (OR:0.23, CI: 0.1, 0.5), CVD (OR:0.44, CI: 0.22, 0.87), dyslipidemia (OR:0.38, CI: 0.13, 1.05), whereas sensitization to house dust mite was associated with a higher remission rate (OR:2.06, CI: 1.03, 4.17). During long-term follow-up, significant adjusted predictors of no remission were sputum eosinophils, small airway dysfunction, and airflow obstruction.</div></div><div><h3>Conclusion</h3><div>This study highlights a substantial unmet need in achieving long-term remission, particularly in patients with persistent type 2 inflammation and impaired lung function, prompting re-evaluation of targeting T2 inflammation earlier to prevent lung function impairment.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101127"},"PeriodicalIF":4.3,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145222494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to comment on “Total IgE levels in patients with hematologic malignancies”","authors":"Parisa Amjadi PhD ,&nbsp;Fatemehsadat Hosseini MD ,&nbsp;Ehsan Zaboli MD ,&nbsp;Mohammad Eslami-Jouybari MD ,&nbsp;Hossein Asgarian-Omran PhD ,&nbsp;Akbar Hedayatizadeh-Omran MD, PhD ,&nbsp;Versa Omrani-Nava MSc ,&nbsp;Reza Alizadeh-Navaei MD, PhD","doi":"10.1016/j.waojou.2025.101122","DOIUrl":"10.1016/j.waojou.2025.101122","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101122"},"PeriodicalIF":4.3,"publicationDate":"2025-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145159581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on \"Total IgE and hematologic malignancy development\"","authors":"Öner Özdemir MD","doi":"10.1016/j.waojou.2025.101119","DOIUrl":"10.1016/j.waojou.2025.101119","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101119"},"PeriodicalIF":4.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to Letter to the Editor: “Comment on ‘Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign’”","authors":"Stefania Nicola MD ,&nbsp;Iuliana Badiu MD ,&nbsp;Nicolo Rashidy MD ,&nbsp;Elena Saracco MD ,&nbsp;Erika Montabone MD ,&nbsp;Luca Lo Sardo MD ,&nbsp;Marzia Boem MD ,&nbsp;Valentina Marmora MD ,&nbsp;Federica Corradi MD ,&nbsp;Andrea Ricotti MSc, MPH ,&nbsp;Richard Borrelli MD ,&nbsp;Giovanni Rolla MD ,&nbsp;Simone Negrini MD ,&nbsp;Luisa Brussino MD","doi":"10.1016/j.waojou.2025.101118","DOIUrl":"10.1016/j.waojou.2025.101118","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101118"},"PeriodicalIF":4.3,"publicationDate":"2025-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated multi-omics profiling reveals shared mechanistic pathways in asthma-allergic rhinitis comorbidity: A hybrid machine learning framework leveraging Mendelian randomization for precision diagnostics","authors":"Hehe Wang PhD ,&nbsp;Jiali Tu MMed ,&nbsp;Junge Zhang MMed ,&nbsp;Wenxin Wang MMed ,&nbsp;Ziyi Yuan MMed ,&nbsp;Chunlin Li MMed ,&nbsp;Yaowen Wang MD","doi":"10.1016/j.waojou.2025.101120","DOIUrl":"10.1016/j.waojou.2025.101120","url":null,"abstract":"<div><h3>Background</h3><div>Asthma (AS) and allergic rhinitis (AR), though sharing Th2-driven inflammation, exhibit distinct clinical trajectories, with molecular mechanisms underlying their comorbidity remaining poorly characterized. This study aimed to delineate conserved and divergent immunometabolic pathways and develop a blood-based diagnostic framework integrating multi-omics biomarkers.</div></div><div><h3>Methods</h3><div>We harmonized 8 peripheral blood transcriptomic cohorts (n = 1,073) using ComBat correction, performed Mendelian randomization (MR) across 5 asthma cohorts (FinnGen Release 12), and constructed a combinatorial machine learning model (113 configurations) validated in 5 independent cohorts.</div></div><div><h3>Results</h3><div>Bidirectional regulation of the Y-chromosomal gene RPS4Y1 (upregulated in AR, downregulated in AS) was linked to disease-specific immunometabolic reprogramming (P &lt; 0.001). MR identified 7 causal plasma proteins (GRAMD1C, GSTO1, IL1RAP, MMP9, PDXK, SAT2, SIGLEC12) intersecting transcriptomic signatures, implicating oxidative stress as a shared mechanism. The glmBoost-RF diagnostic model integrating these biomarkers achieved superior accuracy (AUC &gt;95% in 4/5 cohorts), outperforming conventional classifiers reliant on IgE or eosinophils. Immune profiling revealed AR-specific native B-cell expansion and Treg depletion versus AS-associated CD4⁺ T/NK cell activation (P &lt; 0.05). Coordinated dysregulation of Y-chromosomal genes (EIF1AY, KDM5D) suggested sex-dimorphic immune modulation.</div></div><div><h3>Conclusions</h3><div>This integrative analysis establishes RPS4Y1 as a central regulator of allergic inflammation dimorphism and delivers a validated multi-omics classifier for precision diagnostics. The findings bridge molecular sex differences, metabolic-immune crosstalk, and clinical heterogeneity, advancing phenotype-specific therapeutic strategies.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101120"},"PeriodicalIF":4.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145120992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comment on “Evaluating vaccination dosing strategies for SARS-CoV-2 in patients at high-risk for allergic reactions: Insights from vaccination campaign”","authors":"Hinpetch Daungsupawong PhD ,&nbsp;Viroj Wiwanitkit MD","doi":"10.1016/j.waojou.2025.101121","DOIUrl":"10.1016/j.waojou.2025.101121","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101121"},"PeriodicalIF":4.3,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145121151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A World Allergy Organization (WAO) manifesto for the worldwide approval of biologic therapies for food allergy","authors":"Alessandro Fiocchi MD ,&nbsp;Bryan Martin DO ,&nbsp;Gary Wing-Kin Wong MD ,&nbsp;Motohiro Ebisawa MD, PhD ,&nbsp;Lucia Lo Scalzo ,&nbsp;Francesca Galletta MD ,&nbsp;Stefania Arasi MD, MSc, PhD ,&nbsp;Ignacio J. Ansotegui MD, PhD ,&nbsp;Maryam Ali Al-Nesf Al-Mansouri MD ,&nbsp;Sandra N. Gónzalez Díaz MD, PhD ,&nbsp;Jonathan A. Bernstein MD ,&nbsp;Elham Hossny MD, PhD ,&nbsp;Hiroshi Chantaphakul MD ,&nbsp;Luciana K. Tanno MD, PhD ,&nbsp;Tinatin Chikovani MD, PhD ,&nbsp;David M. Lang MD ,&nbsp;Luz Fonacier MD ,&nbsp;Hideaki Morita MD ,&nbsp;Mary Beth Fasano MD, MSPH ,&nbsp;José Antonio Ortega-Martell MD ,&nbsp;Mário Morais Almeida MD","doi":"10.1016/j.waojou.2025.101113","DOIUrl":"10.1016/j.waojou.2025.101113","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101113"},"PeriodicalIF":4.3,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145097980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characterization of a major house dust mite allergen Der p 22 among Malaysian adult population","authors":"Kavita Reginald PhD ,&nbsp;Smyrna Moti Rawanan Shah MSc ,&nbsp;Amanda Sandra Lestari Lee BSc ,&nbsp;Yang Yie Sio PhD ,&nbsp;Fook Tim Chew PhD","doi":"10.1016/j.waojou.2025.101117","DOIUrl":"10.1016/j.waojou.2025.101117","url":null,"abstract":"<div><h3>Background</h3><div>House dust mites (HDM) are a major trigger factor of allergic diseases worldwide.</div></div><div><h3>Objective</h3><div>To characterize the group 22 allergen from the HDM <em>Dermatophagoides pteronyssinus</em> among Malaysian atopic adults.</div></div><div><h3>Methods</h3><div>Recombinant Der p 22 and 33 alanine mutants were expressed in <em>Escherichia coli</em> and purified. Specific IgE levels to group 22 allergens were measured in serum samples from a combined cohort of Malaysian adults (n = 176) and participants from the SMCGES sub-cohort (n = 755), with responses classified by ImmunoCAP classes. Age- and gender-adjusted multivariate logistic regression was used to assess associations between Class 3+ group 22-specific IgE responses (&gt;3.5 IU/mL) and clinical diagnoses of asthma, allergic rhinitis (AR), and atopic dermatitis (AD). IgE inhibition assays were performed to evaluate the presence of unique epitopes in Der p 22 relative to its homologue Der p 2. Epitope mapping was performed using 33 single-alanine substitution mutants of Der p 22. Statistical analyses were carried out using GraphPad Prism and logistic regression models.</div></div><div><h3>Results</h3><div>Recombinant Der p 22 was expressed and purified as a 17.2 kDa protein. Among 149 atopic Malaysian adults, 54% had detectable sIgE to Der p 22. IgE inhibition assays demonstrated partial cross-reactivity between Der p 22 and Der p 2. High-level group 22-specific IgE responses (Class 3+) were associated with an increased risk of asthma (OR = 1.73, 95% CI = 0.98–3.00, p = 0.0524) and significantly associated with the presence of atopic comorbidities including AR and AD (all p &lt; 0.05). Epitope mapping identified to 6 critical residues, K10, H35, R43, D106, R117 and R130, where alanine substitution led to a marked reduction in IgE binding (median reduction &gt;95%).</div></div><div><h3>Conclusion</h3><div>Der p 22 is a clinically relevant HDM allergen in the Malaysian adult population. It harbours both unique and shared IgE epitopes with Der p 2, highlighting its value for inclusion in molecular diagnostic panels to improve allergen sensitization profiling. Alanine mutation to 6 amino acid residues of Der p 22 significantly reduced IgE binding, suggesting its potential as a candidate hypoallergen molecule in allergen-specific immunotherapy.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101117"},"PeriodicalIF":4.3,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145098033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Managing in-flight allergic emergencies: Challenges and solutions","authors":"Rita Aguiar MD,&nbsp;Raquel Baptista-Pestana MD,&nbsp;Mário Morais-Almeida MD","doi":"10.1016/j.waojou.2025.101114","DOIUrl":"10.1016/j.waojou.2025.101114","url":null,"abstract":"","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101114"},"PeriodicalIF":4.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between circulating thyroperoxidase (TPO), anti-TPO IgE, anti-TPO IgG, and different clinical outcomes in chronic urticaria: A hypothesis-generating study","authors":"Juan-Felipe Lopez MD, MSc, PhD(c) ,&nbsp;Valentina Bedoya MSc ,&nbsp;Julián-Camilo Arango MSc, PhD ,&nbsp;Tonny-Williams Naranjo MSc, PhD ,&nbsp;Elizabeth Garcia MD, EAC ,&nbsp;Jorge Sanchez MD, EAC, MSc, PhD","doi":"10.1016/j.waojou.2025.101116","DOIUrl":"10.1016/j.waojou.2025.101116","url":null,"abstract":"<div><h3>Background</h3><div>In chronic spontaneous urticaria (CSU), multiple biomarkers have been described, including autoantibodies against thyroperoxidase (TPO). However, the simultaneous analysis of both IgE anti-TPO and IgG anti-TPO alongside blood TPO has not been performed.</div></div><div><h3>Objective</h3><div>We conducted this hypothesis-generating study to evaluate the association between blood TPO, anti-TPO IgE, and anti-TPO IgG and explore their relationships with some clinical variables.</div></div><div><h3>Methods</h3><div>Patients aged 12–80 years with a clinical diagnosis of CSU were included in this study. First, the biomarkers between a CSU group and a non-CSU group were compared (case–control design). Second, the relationship between the biomarkers and clinical characteristics was explored in the CSU group with a twelve-month follow-up.</div></div><div><h3>Results</h3><div>The blood concentration of TPO was higher in the CSU group than in the control group, though this was not statistically significant (median 3.8 ng/mL vs. 13.3 ng/mL <em>p</em> = 0.4). The blood concentration of TPO was not associated with the presence of anti-TPO IgE or IgG. A total of 42 patients (61.2% versus 9.3% in non-CSU group) had anti-TPO IgG (29.4%) or anti-TPO IgE (42.6%) autoantibodies, and 7 patients (10.2%) had both. In the exploratory analysis, anti-TPO IgE and anti-TPO IgG were associated with different clinical clusters.</div></div><div><h3>Conclusion</h3><div>In this hypothesis-generating study, TPO levels do not appear to determine the presence of autoantibodies in patients with CSU. About half of patients with CSU have either an IgE or IgG autoantibody against TPO, but few patients have both, and each autoantibody is associated with a different clinical profile, suggesting that there are perhaps independent CSU mechanisms with a common target. Future studies are required to confirm this hypothesis.</div></div>","PeriodicalId":54295,"journal":{"name":"World Allergy Organization Journal","volume":"18 10","pages":"Article 101116"},"PeriodicalIF":4.3,"publicationDate":"2025-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145050575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}